Prof Kevin Baird


Professor J. Kevin Baird, BSc, MSc, PhD, FASTMH


Head of Unit, Eijkman-Oxford Clinical Research Unit, Jakarta


Kevin Baird  is the Head of Eijkman-Oxford Clinical Research Unit in Jakarta, Indonesia, and Professor of Malariology, Nuffield Department of Medicine, University of Oxford. He earned a B.Sc. in Microbiology, M.Sc. in Biochemistry from University of Maryland, and a Ph.D. in Medical Zoology from Tulane University. He has long focused on Plasmodium vivax malaria, in particular on the problems of G6PD deficiency and cytochrome P-450 2D6 pharmacogenetics regarding the toxicity and efficacy of primaquine therapy against relapse of that species. His laboratory undertakes clinical trials of therapies against relapse of P. vivax, principally in Indonesian soldiers but also in village settings, in addition to laboratory and field studies of G6PD deficiency biochemistry, diagnostics, and epidemiology.


Dr Baird has published over 140 technical articles and 80 reviews, chapters and letters.

Key technical articles

Baird JK, Louisa M, Noviyanti R, Ekawati L, Elyazar IR, et al. 2018. Association of impaired cytochrome P-450 2D6 activity genotype and phenotype with therapeutic efficacy of primaquine for treatment of latent Plasmodium vivax malaria. JAMA Network Open 1: e181449.

Sutanto I, Kosasih A, Elyazar IRF, Simanjutak DR, Larasati TA, et al. 2018. Negligible impact of mass screening and treatment on mesoendemic malaria transmission at West Timor in eastern Indonesia: a cluster-randomized trial. Clinical Infectious Diseases 67: 1364-72.

Nelwan EJ, Ekawati LL, Tjahjono B, Setiabudy R, Sutanto I, Chand K, Ekasari T, Djoko D, Basri H, Taylor WR, Duparc S, Subekti D, Elyazar I, Noviyanti R, Sudoyo H, Baird JK. 2015. Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia. BMC Medicine 13: 294.

Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Melia RA, Setiabudy R, Nurliela S, Ekawati LL, Elyazar I, Farrar J, Sodoyo H, Baird JK. 2013. Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrobial Agents & Chemotherapy 57: 1128-1135.

Key books/monographs etc

Baird JK. 2019. 8-Aminoquinoline therapy for latent malaria. Clinical Microbiology Reviews. In press.

Baird JK. 2018. Tafenoquine for travelers’ malaria: evidence, rationale and recommendations. Journal of Travel Medicine 25: doi: 10.1093/jtm/tay110.

Baird JK. 2017. Malaria control by commodities without practical malariology. BMC Public Health 17: 590.

Nguyen TD, Olliaro P, Dondorp AM, Baird JK, Lam HM, Farrar J, Thwaites GE, White NJ, Boni MF. 2016. Optimum population-level use of artemisinin-combined therapies: a modelling study. Lancet Global Health 2015; 3: e758-766.

Baird JK, Valecha N, Duparc S, White NJ, Price RN. 2016. Diagnosis and treatment of Plasmodium vivax malaria. American Journal of Tropical Medicine and Hygiene 95(6 Suppl): 35-51.

Baird JK. 2015. G6PD diagnostics for Plasmodium vivax malaria is clinical and public health urgency. BMC Medicine 13: 296.

Baird JK. 2013. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clinical Microbiology Reviews 26: 36-57.

Doolan DL, Dobano C, Baird JK. 2009. Acquired immunity to malaria. Clinical Microbiology Reviews 22: 13-36.

Baird JK. 2009. Resistance to therapies for Plasmodium vivax. Clinical Microbiology Reviews 22: 508-34.

Hay SI, Price R, Baird JK (eds). The Epidemiology of Plasmodium vivax: History, Hiatus, and Hubris, Parts A & B. Advances in Parasitology 2012 & 2013, volumes 80 & 81, 356 & 267 pp.

Baird JK. 2005. Effectiveness of antimalarial drugs. New England Journal of Medicine 352: 1565-77.

Dr Baird’s Google Scholar profile